OPRX - OptimizeRx Corp Stock Price, Fair Value and News

12.73USD-0.12 (-0.93%)Market Closed

Market Summary

USD12.73-0.12

Market Closed

-0.93%

OPRX Stock Price

View Fullscreen

OPRX RSI Chart

OPRX Valuation

Market Cap

232.6M

Price/Earnings (Trailing)

-12.87

Price/Sales (Trailing)

2.97

EV/EBITDA

-16.1

Price/Free Cashflow

-45.41

OPRX Price/Sales (Trailing)

OPRX Profitability

Operating Margin

60.95%

EBT Margin

-25.55%

Return on Equity

-14.74%

Return on Assets

-10.24%

Free Cashflow Yield

-2.2%

OPRX Fundamentals

OPRX Revenue

Revenue (TTM)

78.2M

Rev. Growth (Yr)

51.43%

Rev. Growth (Qtr)

-30.59%

OPRX Earnings

Earnings (TTM)

-18.1M

Earnings Growth (Yr)

-7.84%

Earnings Growth (Qtr)

-66.59%

Breaking Down OPRX Revenue

Last 7 days

17.8%

Last 30 days

33.6%

Last 90 days

-19.4%

Trailing 12 Months

5.6%

How does OPRX drawdown profile look like?

OPRX Financial Health

Current Ratio

2.88

Debt/Equity

0.26

Debt/Cashflow

-0.16

OPRX Investor Care

Shares Dilution (1Y)

6.67%

Diluted EPS (TTM)

-1.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	78.2M	0	0	0
2023	61.7M	61.6M	62.8M	71.5M
2022	63.8M	64.1M	63.1M	62.5M
2021	47.0M	51.8M	57.4M	61.3M
2020	27.0M	28.8M	34.3M	43.3M
2019	22.3M	24.2M	23.8M	24.6M
2018	14.1M	16.3M	18.6M	21.2M
2017	8.1M	9.1M	10.4M	12.1M
2016	7.5M	7.7M	7.5M	7.8M
2015	6.7M	7.0M	7.2M	7.2M
2014	5.3M	5.6M	6.2M	6.5M
2013	2.3M	2.9M	3.7M	4.7M
2012	1.0M	1.4M	1.6M	2.0M
2011	331.2K	591.3K	851.4K	1.1M
2010	0	0	0	71.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of OptimizeRx Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	silvestro stephen l	sold (taxes)	-378,940	10.7	-35,415	chief commercial officer
May 02, 2024	silvestro stephen l	acquired	-	-	90,000	chief commercial officer
Apr 15, 2024	febbo william j	acquired	-	-	60,000	ceo
Mar 15, 2024	silvestro stephen l	acquired	-	-	7,750	chief commercial officer
Mar 01, 2024	silvestro stephen l	acquired	-	-	1,927	chief commercial officer
Mar 01, 2024	silvestro stephen l	sold (taxes)	-9,123	15.95	-572	chief commercial officer
Mar 01, 2024	odence-ford marion	acquired	-	-	771	general counsel and cco
Mar 01, 2024	odence-ford marion	sold (taxes)	-4,274	15.95	-268	general counsel and cco
Mar 01, 2024	silvestro stephen l	sold (taxes)	-10,654	15.95	-668	chief commercial officer

Which funds bought or sold OPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	342,083	342,083	-%
May 16, 2024	COMERICA BANK	unchanged	-	-61.00	340	-%
May 16, 2024	AVENIR CORP	unchanged	-	-190,642	1,072,360	0.09%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-39.76	-18,603	19,476	-%
May 16, 2024	AWM Investment Company, Inc.	added	4.02	-1,370,340	10,364,500	1.36%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	reduced	-99.35	-8,799	49.00	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-443,195	-	-%
May 15, 2024	MORGAN STANLEY	reduced	-5.03	-215,988	899,168	-%
May 15, 2024	KENNEDY CAPITAL MANAGEMENT LLC	reduced	-34.83	-3,136,140	3,885,560	0.08%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-27.64	-307,365	489,645	-%

Are Funds Buying or Selling OPRX?

Are funds buying OPRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OPRX

No. of Funds

Unveiling OptimizeRx Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	first light asset management, llc	9.52%	1,728,430	SC 13G
Feb 13, 2024	vanguard group inc	5.62%	1,021,002	SC 13G/A
Jan 29, 2024	blackrock inc.	6.3%	1,134,954	SC 13G/A
Dec 29, 2023	divisadero street capital management, lp	5.2%	949,550	SC 13G
Nov 28, 2023	weintraub michael	7.6%	1,384,467	SC 13G
Jun 09, 2023	first light asset management, llc	10.28%	1,760,596	SC 13G
Apr 06, 2023	blackrock inc.	6.1%	1,041,738	SC 13G/A
Feb 09, 2023	vanguard group inc	6.48%	1,111,411	SC 13G/A
Jan 23, 2023	blackrock inc.	15.8%	2,714,190	SC 13G/A
Feb 11, 2022	blair william & co/il	4.1%	730,674	SC 13G/A

Recent SEC filings of OptimizeRx Corp

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 06, 2024	4	Insider Trading
May 06, 2024	4/A	Insider Trading
May 06, 2024	4/A	Insider Trading
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 24, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading

Peers (Alternatives to OptimizeRx Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

OptimizeRx Corp News

Latest updates

OptimizeRx Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-30.6%	19,690,000	28,368,946	16,331,484	13,818,166	13,002,910	19,654,457	15,085,504	13,978,665	13,731,530	20,312,797	16,124,951	13,625,639	11,229,211	16,426,301	10,519,191	8,783,230	7,584,602	7,379,782	5,002,767	7,006,291	5,209,434
Cost Of Revenue	-28.9%	7,486,000	10,527,640	6,531,183	5,993,145	5,569,621	7,200,029	5,664,733	4,988,716	5,629,858	7,920,985	7,047,832	5,580,964	5,104,603	7,822,280	4,504,844	3,639,016	3,241,763	2,906,933	1,981,143	2,687,143	1,583,480
Gross Profit	-31.6%	12,204,000	17,841,306	9,800,301	7,825,021	7,433,289	12,454,428	9,420,771	8,989,949	8,101,672	12,391,813	9,077,119	8,044,675	6,124,608	8,604,021	6,014,347	5,144,214	4,342,839	4,472,849	3,021,624	4,319,148	3,625,954
Operating Expenses	-40.0%	17,233,000	28,744,479	13,353,789	12,706,889	14,496,475	13,318,776	13,177,530	12,898,479	11,862,773	11,770,733	9,038,929	7,704,536	6,762,916	7,247,553	6,191,069	6,200,027	6,602,091	6,791,312	5,008,934	3,839,105	3,493,789
S&GA Expenses	-	-	-	12,887,083	12,242,128	14,032,542	-2,883,591	12,661,703	12,320,362	11,391,233	18,911,453	3,411,602	2,900,702	2,474,946	-	-	-	-	-	-	-	-
EBITDA Margin	-Infinity%	-0.20	-	-0.19	-0.20	-0.20	-0.15	-0.13	-0.08	-0.01	0.04	0.06	0.06	0.03	-	-	-	-	-	-	-	-
Interest Expenses	-	1,546,000	-	-	-	-	-163	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	344,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-6,555,000	-	-2,865,298	-4,161,449	-6,397,714	-325,836	-3,466,792	-3,884,714	-3,761,098	623,462	39,894	352,100	-637,377	1,357,166	-282,894	-1,077,468	-2,203,931	-2,882,740	-1,570,942	406,617	6,529
EBT Margin	-Infinity%	-0.26	-	-0.22	-0.23	-0.23	-0.18	-0.17	-0.11	-0.04	0.01	0.02	0.02	-0.01	-	-	-	-	-	-	-	-
Net Income	-66.6%	-6,899,000	-4,141,405	-2,865,298	-4,161,449	-6,397,714	-325,836	-3,466,792	-3,884,714	-3,761,098	623,462	39,894	352,100	-637,377	1,357,166	-282,894	-1,077,468	-2,203,931	-1,984,780	-1,570,942	406,617	6,529
Net Income Margin	5.9%	-0.23	-0.25	-0.22	-0.23	-0.23	-0.18	-0.17	-0.11	-0.04	0.01	0.02	0.02	-	-	-	-	-	-	-	-	-
Free Cashflow	133.7%	2,112,694	-6,262,524	1,439,343	-2,388,135	-114,910	2,787,146	3,438,890	281,273	4,065,764	-1,372,300	186,017	166,121	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.8%	176	183	124	121	132	135	136	147	138	141	135	132	128	60.00	55.00	56.00	56.00	57.00	49.00	50.00	25.00
Current Assets	-11.0%	48.00	54.00	87.00	85.00	96.00	99.00	99.00	110	113	115	108	105	101	33.00	27.00	28.00	27.00	27.00	38.00	39.00	15.00
Cash Equivalents	9.6%	15.00	14.00	10.00	10.00	16.00	18.00	41.00	87.00	89.00	85.00	85.00	84.00	82.00	11.00	12.00	14.00	15.00	19.00	30.00	31.00	10.00
Net PPE	2.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0.0%	78.00	78.00	23.00	23.00	23.00	23.00	23.00	23.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	4.00	4.00	4.00
Liabilities	-5.3%	54.00	57.00	8.00	6.00	8.00	9.00	6.00	7.00	7.00	10.00	8.00	7.00	6.00	10.00	8.00	13.00	13.00	12.00	7.00	8.00	6.00
Current Liabilities	-6.2%	17.00	18.00	8.00	6.00	8.00	8.00	6.00	6.00	7.00	9.00	8.00	7.00	5.00	10.00	8.00	12.00	9.00	6.00	5.00	6.00	4.00
Long Term Debt	-5.3%	32.00	34.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	75.0%	4.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-3.2%	123	127	116	116	124	126	130	141	131	131	127	125	122	50.00	47.00	44.00	44.00	45.00	41.00	42.00	19.00
Retained Earnings	-10.7%	-71.16	-64.26	-60.12	-57.25	-53.09	-46.69	-46.37	-42.90	-39.01	-35.25	-35.88	-35.92	-36.27	-35.63	-36.99	-36.71	-35.63	-33.42	-31.44	-29.87	-30.28
Additional Paid-In Capital	1.5%	194	191	176	173	177	173	176	184	170	167	163	161	158	86.00	84.00	80.00	79.00	78.00	73.00	72.00	50.00
Shares Outstanding	6.2%	18.00	17.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	17.00	17.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	235	-	-	-	487	-	-	-	1,030	-	-	-	185	-	-	-	222	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	133.8%	2,118	-6,257	1,473	-2,368	-86.33	2,803	3,462	308	4,080	-1,334	205	190	1,666	-2,592	-106	128	-3,738	-1,499	-969	-81.77	890
Share Based Compensation	15.1%	3,024	2,627	3,206	3,503	4,381	4,269	4,277	4,025	3,174	3,067	1,008	897	582	1,106	631	681	755	852	470	408	530
Cashflow From Investing	99.4%	-153	-26,001	-1,009	3,223	-1,548	-18,484	-37,505	-2,120	-65.75	-99.02	-166	-135	-84.56	-79.47	-20.26	-9.06	-15.94	-9,520	-13.72	-1,033	-13.85
Cashflow From Financing	-101.8%	-640	36,189	-349	-7,490	-129	-7,439	-12,020	251	258	1,059	1,095	1,591	70,181	1,156	-1,954	-1,214	112	113	206	21,518	344
Buy Backs	-	-	-	-	7,522	-	7,463	12,241	321	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OPRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 19,690	$ 13,003
Cost of revenues, exclusive of depreciation and amortization presented separately below	7,486	5,570
Gross profit	12,204	7,433
Operating expenses
General and administrative expenses	16,166	14,032
Depreciation and amortization	1,067	464
Total operating expenses	17,233	14,496
Loss from operations	(5,029)	(7,063)
Other income (expense)
Interest expense	(1,546)
Interest income	20	665
Total other income (expense), net	(1,526)	665
Loss before provision for income taxes	(6,555)	(6,398)
Provision for income taxes	(344)
Net loss	$ (6,899)	$ (6,398)
Weighted average number of shares outstanding – basic (in Shares)	18,170,108	17,094,676
Weighted average number of shares outstanding – diluted (in Shares)	18,170,108	17,094,676
Loss per share – basic (in Dollars per share)	$ (0.38)	$ (0.37)
Loss per share – diluted (in Dollars per share)	$ (0.38)	$ (0.37)

OPRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 15,177	$ 13,852
Accounts receivable, net of allowance for credit losses of $371 and $480 at March 31, 2024 and December 31, 2023, respectively	29,748	36,253
Taxes receivable	1,036	1,036
Prepaid expenses and other	2,390	3,190
Total current assets	48,351	54,331
Property and equipment, net	153	149
Other assets
Goodwill	78,357	78,357
Other intangibles, net	14,882	15,198
Tradename and customer relationships, net	33,596	34,198
Operating lease right of use assets, net	527	573
Security deposits and other assets	501	568
Total other assets	127,863	128,894
TOTAL ASSETS	176,367	183,374
Current liabilities
Current portion of long-term debt	3,500	2,000
Accounts payable – trade	1,665	2,227
Accrued expenses	7,278	7,706
Revenue share payable	2,814	5,506
Taxes payable	371	49
Current portion of lease liabilities	233	222
Deferred revenue	904	172
Total current liabilities	16,765	17,882
Non-current liabilities
Long-term debt, net	32,413	34,231
Lease liabilities, net of current portion	314	371
Deferred tax liabilities, net	4,337	4,337
Total liabilities	53,829	56,821
Commitments and contingencies (See note 10)
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at March 31, 2024 or December 31, 2023
Common stock, $0.001 par value, 166,666,667 shares authorized, 19,921,879 and 19,899,679 shares issued at March 31, 2024 and December 31, 2023, respectively	20	20
Treasury stock, $0.001 par value, 1,741,397 shares held at March 31, 2024 and December 31, 2023	(2)	(2)
Additional paid-in-capital	193,677	190,793
Accumulated deficit	(71,157)	(64,258)
Total stockholders’ equity	122,538	126,553
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 176,367	$ 183,374

About OptimizeRx Corp

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.

CEO	Mr. William J. Febbo
WEBSITE	optimizerx.com
INDUSTRY	Healthcare Plans
EMPLOYEES	109

OptimizeRx Corp Frequently Asked Questions

What is the ticker symbol for OptimizeRx Corp? What does OPRX stand for in stocks?

OPRX is the stock ticker symbol of OptimizeRx Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OptimizeRx Corp (OPRX)?

As of Fri May 17 2024, market cap of OptimizeRx Corp is 232.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPRX stock?

You can check OPRX's fair value in chart for subscribers.

What is the fair value of OPRX stock?

You can check OPRX's fair value in chart for subscribers. The fair value of OptimizeRx Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OptimizeRx Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OptimizeRx Corp a good stock to buy?

The fair value guage provides a quick view whether OPRX is over valued or under valued. Whether OptimizeRx Corp is cheap or expensive depends on the assumptions which impact OptimizeRx Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPRX.

What is OptimizeRx Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OPRX's PE ratio (Price to Earnings) is -12.87 and Price to Sales (PS) ratio is 2.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on OptimizeRx Corp's stock?

In the past 10 years, OptimizeRx Corp has provided 0.242 (multiply by 100 for percentage) rate of return.